A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.

Pfizer

Status and phase: Terminated; Phase 2

Conditions: Pain

Treatments: Drug: [S,S]-Reboxetine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00353808

A6061029

Details and patient eligibility

About

The purpose of this study is to assess the long-term safety and tolerability of [S,S]-Reboxetine in patients with chronic pain following shingles. This is the extension study of Protocol A6061026.

Enrollment: 112 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have met the patient selection criteria for the preceding double-blind Protocol A6061026 and have completed the 16-week trial.
• Patients at screening must have a score of >/=40mm on the pain visual analogue scale.

Exclusion criteria

• Serious adverse event during the preceding double-blind Protocol A6061026 that was determined to be related to the trial medication by the Investigator.
• Patient treatment compliance was less than 80% in the preceding double-blind Protocol A6061026.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

112 participants in 1 patient group

s, s reboxetine

Experimental group

Treatment:

Drug: [S,S]-Reboxetine